Nothing Special   »   [go: up one dir, main page]

MA27500A1 - PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - Google Patents

PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE

Info

Publication number
MA27500A1
MA27500A1 MA28329A MA28329A MA27500A1 MA 27500 A1 MA27500 A1 MA 27500A1 MA 28329 A MA28329 A MA 28329A MA 28329 A MA28329 A MA 28329A MA 27500 A1 MA27500 A1 MA 27500A1
Authority
MA
Morocco
Prior art keywords
inhibitor
alzheimer
disease
prevention
treatment
Prior art date
Application number
MA28329A
Other languages
French (fr)
Inventor
Thierry Canton
Laurent Pradier
Jesus Benavides
Hubert Heuer
Hans-Ludwig Schaefer
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MA27500A1 publication Critical patent/MA27500A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention a pour objet l'application des inhibiteurs de recapture intestinale de l'acide biliaire pour la prévention et le traitement de la maladie d'Alzheimer, le cas échéant en association avec un inhibiteur de HMG-CoA réductase, un inhibiteur de la capture de cholestérol, un inhibiteur de la synthèse de cholestérol ou un inhibiteur des APP secrétases.The subject of the invention is the application of inhibitors of intestinal reuptake of bile acid for the prevention and treatment of Alzheimer's disease, where appropriate in combination with an inhibitor of HMG-CoA reductase, an inhibitor of cholesterol capture, a cholesterol synthesis inhibitor or an APP secretase inhibitor.

MA28329A 2002-12-12 2005-06-10 PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE MA27500A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (en) 2002-12-12 2002-12-12 APPLICATION OF INTESTINAL BILIARY ACID RECAPTURE INHIBITORS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE

Publications (1)

Publication Number Publication Date
MA27500A1 true MA27500A1 (en) 2005-08-01

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28329A MA27500A1 (en) 2002-12-12 2005-06-10 PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE

Country Status (22)

Country Link
EP (1) EP1572174A1 (en)
JP (1) JP2006514063A (en)
KR (1) KR20050084250A (en)
CN (1) CN1726016A (en)
AR (1) AR042354A1 (en)
AU (1) AU2003296802A1 (en)
BR (1) BR0317280A (en)
CA (1) CA2507945A1 (en)
CO (1) CO5700712A2 (en)
FR (1) FR2848452B1 (en)
HR (1) HRP20050534A2 (en)
MA (1) MA27500A1 (en)
MX (1) MXPA05005556A (en)
NO (1) NO20053341L (en)
NZ (1) NZ540496A (en)
PE (1) PE20040770A1 (en)
PL (1) PL377110A1 (en)
RS (1) RS20050420A (en)
RU (1) RU2005121909A (en)
TW (1) TW200503707A (en)
WO (1) WO2004062652A1 (en)
ZA (1) ZA200504656B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
CA2589102C (en) 2004-11-02 2013-08-13 Northwestern University Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
MX2009012583A (en) * 2007-05-22 2010-03-08 Otsuka Pharma Co Ltd A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease.
US20140243281A1 (en) * 2011-10-28 2014-08-28 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP2770990A4 (en) 2011-10-28 2015-03-11 Lumena Pharmaceuticals Inc BILY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF HYPERCHOLEMIA AND HEPATIC CHOLESTATIC DISEASE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
ATE231723T1 (en) * 1991-02-22 2003-02-15 Howard K Shapiro USE OF PHARMACEUTICAL ACTIVE INGREDIENTS FOR THE TREATMENT OF DISEASE SYMPTOMS OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOM COMPLEXES
WO1997049736A2 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
CA2311356C (en) * 1998-01-28 2004-07-13 Warner-Lambert Company Method for treating alzheimer's disease
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (en) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxide derivatives, processes for their preparation and medicaments containing these compounds
DE19845405C2 (en) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Aryl-substituted propanolamine derivatives and their use
AU2001233299A1 (en) * 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (en) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
WO2004062652A1 (en) 2004-07-29
BR0317280A (en) 2005-11-08
PL377110A1 (en) 2006-01-23
AR042354A1 (en) 2005-06-15
AU2003296802A1 (en) 2004-08-10
MXPA05005556A (en) 2005-07-26
PE20040770A1 (en) 2004-12-10
ZA200504656B (en) 2006-08-30
NO20053341L (en) 2005-09-07
RS20050420A (en) 2007-04-10
RU2005121909A (en) 2006-01-20
JP2006514063A (en) 2006-04-27
CN1726016A (en) 2006-01-25
TW200503707A (en) 2005-02-01
FR2848452A1 (en) 2004-06-18
EP1572174A1 (en) 2005-09-14
CO5700712A2 (en) 2006-11-30
CA2507945A1 (en) 2004-07-29
NO20053341D0 (en) 2005-07-08
FR2848452B1 (en) 2007-04-06
HRP20050534A2 (en) 2006-11-30
KR20050084250A (en) 2005-08-26
NZ540496A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
GB0223040D0 (en) Therapeutic compounds
ATE443043T1 (en) PHENYLCARBOXAMIDE AS A BETA-SECRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
FR13C0060I2 (en) FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYLUREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS
EP1910829A4 (en) PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE
HUP0301281A2 (en) New pharmaceutical composition
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
TNSN98155A1 (en) COMBINATIONS OF PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN AND ANTIHYPERTENSITIVE AGENTS, AND PROCESS FOR THEIR PREPARATION
EP1769791A3 (en) Treatment of Alzheimer's disease with cell cycle inhibitors
NO20065117L (en) Composition comprising a JNK inhibitor and cyclosporin.
DE602004007808D1 (en) NEW GAMMA SECRETASE INHIBITORS
IL229124A0 (en) Inhibitors of the mutant form of kit
MY133332A (en) Pyrrolidone derivatives as maob inhibitors
NO20053855D0 (en) 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases.
MA27500A1 (en) PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE
MXPA05009986A (en) Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders.
MA29531B1 (en) NEW PROCESS FOR TREATING HYPERLIPIDEMIA
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
ATE550039T1 (en) AGENTS FOR THE TREATMENT OF GLOMERULAR DISEASES
ATE423102T1 (en) 4-SUBSTITUTED-5-CYANO-1H-PYRIMIDINE-6-(TH)IONES AS A GSK-3 INHIBITOR
EP1726313A4 (en) MEDICINE FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS
WO2004028456A3 (en) Method and composition for treating neurodegenerative disorders
AU2002235924A1 (en) Cyp46 genotype determination for risk and treatment evaluation of alzheimer's disease
EP1669085A4 (en) THERAPEUTIC AGENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER'S DISEASE
DE60126504D1 (en) USE OF CANDIDA-EFFECTIVE AGENTS FOR THE TREATMENT OF DISORDERS OF ORAL AND INTESTINAL MUCOSA